Abeona Therapeutics (ABEO) Misses Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
November 14, 2022 7:30 AM ESTFollowing positive topline data from Phase 3 VIITAL study of EB-101 with both co-primary endpoints met, Abeona plans to submit BLA to U.S. FDA in 2Q 2023
Company well-funded with expected cash runway into 3Q 2024
NEW YORK and CLEVELAND, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced financial results for the third quarter of 2022.
The positive topline data from the Phase 3 VIITAL study provides strong support for EB-101s potential and validation of the... More
